Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1 Transcript
All right. Good morning, everyone, and thank you for joining us for this RNAi roundtable. Today, we're going to be discussing our lumasiran franchise, which is now largely focused on OXLUMO, which is indicated for the treatment of primary hyperoxaluria type 1, but we're also excited to briefly discuss our plans for lumasiran in recurrent stone formers with our new Phase II program.
Hi, everyone. My name is Josh Brodsky, I'm Senior Director of Investor Relations and Corporate Communications at Alnylam. And with me today, I am pleased to have Jeroen Valkenburg, Senior Director, Lumasiran Franchise Lead; John Gansner, Director of Clinical Research and Clinical Lead for the lumasiran franchise and also Dr. Jeffrey Saland, Professor at the Icahn School of Medicine at Mount Sinai in New York and a key opinion leader in the treatment of PH1.
Today's RNAi roundtable is the fourth in a series of roundtable webinars that we're hosting over the next few months to review progress across our various
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
